Xuanzhu Pharma Co. Ltd. has divulged poly (ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of atherosclerosis, cancer, epilepsy, hyperlipidemia, ischemia, osteoarthritis, pain and Alzheimer’s disease.
Sitryx Therapeutics Ltd. has identified compounds acting as pyruvate kinase M2 (PKM2) and/or PKLR activators reported to be useful for the treatment of cancer, obesity, inflammation, diabetes and hematologic disorders.
Petra Pharma Corp. has synthesized phosphatidylinositol 3-kinase α (PI3Kα) inhibitors, particularly H1047R and/or E545K mutant allosteric inhibitors. They are described as potentially useful for the treatment of cancer, PIK3CA-related overgrowth spectrum, congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities.
News comes from the U.K. Intellectual Property Office at the beginning of May 2024, where Ethicon, a Johnson & Johnson MedTech company, applied for five additional years patent protection for its Ethizia hemostatic sealing patch, whose embedded Pox polymer system dehydrates blood and accelerates the coagulation cascade to in occur in seconds, forming a tight yet flexible seal that maintains a barrier to bleeding.
Meliora Therapeutics Inc. has patented cyclin-dependent kinase 11 (CDK11) inhibitors and apoptosis inducers reported to be useful for the treatment of breast cancer and melanoma.
The Shanghai Institute of Materia Medica of the Chinese Academy of Sciences, Suzhou Vigonvita Life Sciences Co. Ltd. and the Wuhan Institute of Virology at the Chinese Academy of Sciences have divulged 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).
Rakovina Therapeutics Inc. has described dual NAD+ ADP-ribosyltransferase (poly(ADP-ribose) polymerase; PARP) and histone deacetylase (HDAC) inhibitors reported to be useful for the treatment of Ewing sarcoma.
Merck Sharp & Dohme LLC has disclosed diacylglycerol acyltransferase type 2 (DGAT2) inhibitors reported to be useful for the treatment of atherosclerosis, type 2 diabetes, fibrosis, heart failure, hepatic steatosis, hypercholesterolemia, hyperlipidemia and obesity, among others.
Bristol Myers Squibb Co. has identified proteolysis targeting chimera (PROTAC) compounds comprising a E3 ubiquitin ligase-binding moiety coupled to a proto-oncogene tyrosine-protein kinase receptor Ret (RET; CDHF12; PTC) targeting moiety through a linker reported to be useful for the treatment of cancer.
RSS
